Cite
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
MLA
De Icco, Roberto, et al. “Does MIDAS Reduction at 3 Months Predict the Outcome of Erenumab Treatment? A Real-World, Open-Label Trial.” Journal of Headache & Pain, vol. 23, no. 1, Sept. 2022, pp. 1–14. EBSCOhost, https://doi.org/10.1186/s10194-022-01480-2.
APA
De Icco, R., Vaghi, G., Allena, M., Ghiotto, N., Guaschino, E., Martinelli, D., Ahmad, L., Corrado, M., Bighiani, F., Tanganelli, F., Bottiroli, S., Cammarota, F., Sances, G., & Tassorelli, C. (2022). Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial. Journal of Headache & Pain, 23(1), 1–14. https://doi.org/10.1186/s10194-022-01480-2
Chicago
De Icco, Roberto, Gloria Vaghi, Marta Allena, Natascia Ghiotto, Elena Guaschino, Daniele Martinelli, Lara Ahmad, et al. 2022. “Does MIDAS Reduction at 3 Months Predict the Outcome of Erenumab Treatment? A Real-World, Open-Label Trial.” Journal of Headache & Pain 23 (1): 1–14. doi:10.1186/s10194-022-01480-2.